Question of toxicity of thalidomide in the treatment of leprosy reaction. 1968

J S Berkeley

UI MeSH Term Description Entries
D007918 Leprosy A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid. Hansen's Disease,Hansen Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013792 Thalidomide A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action. Sedoval,Thalomid

Related Publications

J S Berkeley
February 1994, Lancet (London, England),
J S Berkeley
January 1970, Archiv fur klinische und experimentelle Dermatologie,
J S Berkeley
January 1971, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association,
J S Berkeley
September 1967, Archivos argentinos de dermatologia,
J S Berkeley
January 1971, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association,
J S Berkeley
September 2002, Microbes and infection,
J S Berkeley
April 1983, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
J S Berkeley
January 1975, Medicina cutanea ibero-latino-americana,
J S Berkeley
December 1966, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
Copied contents to your clipboard!